MTOR and endometrial cancer: We found that PQR309, a dual PI3K/mTOR inhibitor, reduces proliferation in endometrial cancer cells and endometrial cancer stem cells by decreasing CDK6 and increasing p27 and subsequently inducing G1-phase arrest.